AngioWaveNet vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AngioWaveNet

by AngioWave

ElucidVivo A.3

by Elucid

AI Verdict

AngioWaveNet enhances fluoroscopic angiograms to improve vessel visualization during cardiac catheterization, focusing on procedural clarity. ElucidVivo A.3, however, performs quantitative analysis of arterial plaque from CT angiography for diagnostic and treatment planning purposes. While both tools leverage AI in cardiovascular imaging, their distinct input modalities and primary functions make them adjacent rather than direct competitors.

Choose AngioWaveNet if…

Choose AngioWaveNet if your primary goal is to enhance real-time or near real-time vessel visualization during cardiac catheterization procedures. This tool is ideal for improving clarity and detail in fluoroscopic angiograms, directly integrating into existing cath lab workflows to aid interventionalists. It's particularly useful for optimizing procedural guidance and decision-making during interventions.

View AngioWaveNet →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you require advanced, quantitative analysis of arterial plaque composition and stability from CT angiography for patient stratification and treatment planning. This system is best suited for detailed pre-procedural assessment of atherosclerosis, providing objective measurements of plaque characteristics like Lipid-Rich Necrotic Core (LRNC) and calcifications, and aiding in the derivation of fractional flow reserve (FFRct). It helps optimize treatment decisions by offering a deeper understanding of a patient's cardiovascular risk profile.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AngioWaveNet	ElucidVivo A.3
Pricing	Pricing options include annual software licensing or subscription-based access, tailored to cath lab volume and hospital needs. custom packages are available.	Unknown
Deployment	Cloud-based or on-premise/servers	Cloud and on-premise secure deployment.
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AngioWaveNet

AngioWaveNet emphasizes seamless integration with existing Cath lab workflows and vendor-agnostic compatibility, functioning as a DICOM endpoint, which suggests a straightforward adoption and ease of use within diverse clinical environments. While ElucidVivo A.3 offers advanced visualization features, AngioWaveNet's focus on foundational integration makes it more broadly usable and easier to implement.

Clinical Value

ElucidVivo A.3

ElucidVivo A.3 provides a deeper, quantitative analysis of arterial plaque composition and stability, aiding in patient stratification and treatment optimization, and is validated against ground-truth histology. This offers a more advanced level of clinical insight and direct impact on patient management compared to AngioWaveNet's image enhancement for improved visualization.

Pricing & Value

AngioWaveNet

AngioWaveNet offers transparent pricing models, including annual software licensing or subscription-based access, tailored to cath lab volume and hospital needs, allowing for clearer budget planning. ElucidVivo A.3's 'contact for pricing' provides no immediate insight into cost or value, making it less transparent for potential buyers.

Enterprise Readiness

AngioWaveNet

AngioWaveNet explicitly states HIPAA compliance and offers flexible deployment options (cloud-based or on-premise), alongside vendor-agnostic compatibility and DICOM endpoint functionality. While ElucidVivo A.3 is FDA-cleared and implies HIPAA compliance, AngioWaveNet provides more explicit details regarding its readiness for diverse enterprise environments and regulatory adherence.

Innovation

ElucidVivo A.3

ElucidVivo A.3 demonstrates higher innovation by providing novel quantitative biomarkers for plaque composition and stability, validated against histology, and deriving fractional flow reserve (FFRct). This represents a more advanced and potentially transformative application of AI in cardiovascular diagnostics compared to AngioWaveNet's focus on enhancing image visualization.

Support & Docs

AngioWaveNet

AngioWave Imaging explicitly states that it provides 'full onboarding support, including installation assistance, staff training, and access to ongoing updates and clinical resources'. It also notes that 'minimal training is required' due to intuitive software design. While ElucidVivo A.3 implies support through its FDA clearance and clinical use, AngioWaveNet's explicit mention of comprehensive support and resources gives it an edge.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AngioWaveNet	ElucidVivo A.3
Name	AngioWaveNet	ElucidVivo A.3
Primary Application/Focus	Enhances fluoroscopic angiograms for improved vessel visualization in cardiac catheterization laboratories.	Quantitative analysis of arterial plaque composition and stability from CT angiography to assist in atherosclerosis patient stratification and optimize treatment decisions.
Imaging Modality Supported	Fluoroscopic angiograms	CT angiography
Key AI Functionality	AI-powered Spatiotemporal Enhancement Processing (STEPu2122); improved vessel visualization; post-processing AI for angiographic images.	AI-powered quantitative analysis of arterial plaque (LRNC, matrix, calcifications); 3D visualization of highlighted vessels; derives fractional flow reserve (FFRct).
Specialties	Cardiology, Interventional Radiology, Vascular Surgery	Cardiology, Radiology, Vascular Surgery

Videos

Demos, reviews, and walkthroughs featuring AngioWaveNet and ElucidVivo A.3.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What is the fundamental difference in how AngioWaveNet and ElucidVivo A.3 assist in cardiovascular care?

AngioWaveNet is FDA-cleared AI software that enhances fluoroscopic angiograms for improved vessel visualization in cardiac catheterization laboratories, focusing on procedural clarity. In contrast, ElucidVivo A.3 is an FDA-cleared AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography for diagnostic and treatment planning purposes.

Which imaging modalities do these tools support?

AngioWaveNet is designed to enhance fluoroscopic angiograms and is compatible with any fluoroscopic angiography system. ElucidVivo A.3 performs its quantitative analysis on CT angiography images.

What specific clinical insights or improvements can I expect from each tool?

AngioWaveNet offers improved visibility of blood vessels, vascular structures, and anatomical features in fluoroscopic angiograms, aiding in real-time visualization during interventional cardiology procedures. ElucidVivo A.3 provides objective quantification of plaque components like Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images, along with 3D visualization and derivation of fractional flow reserve (FFRct), to aid in atherosclerosis patient stratification and optimize treatment decisions.

How do these tools integrate into existing clinical workflows?

AngioWaveNet integrates with existing Cath lab workflows and functions as a DICOM endpoint for imaging systems, compatible with any fluoroscopic angiography system. ElucidVivo A.3 is a software application that integrates with PACS/EMR systems, which is standard for medical imaging software.